BOTZ vs XBI
Global X Robotics & Artificial Intelligence ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.68% for BOTZ.
- • BOTZ pays a higher dividend yield (0.54%).
Side-by-side metrics
| Metric | BOTZ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.68% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.54% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $3.04B | $10.92B |
YTD return | -11.96% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.86 | 1.01 |
P/E ratio | 35.20 | — |
Last price | $32.39 | $156.41 |
Inception | — | — |
Issuer | Global X | State Street |
BOTZ top holdings
| ISRG | Intuitive Surgical Inc | 9.94% |
| 6861.T | Keyence Corp | 8.65% |
| 6954.T | Fanuc Corp | 8.59% |
| NVDA | NVIDIA Corp | 7.81% |
| ABBN.SW | ABB Ltd | 7.71% |
| 6273.T | SMC Corp | 4.67% |
| 6383.T | Daifuku Co Ltd | 3.43% |
| 300124.SZ | Shenzhen Inovance Technology Co Ltd Class A | 2.93% |
| CGNX | Cognex Corp | 2.60% |
| TSLA | Tesla Inc | 2.40% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About BOTZ
BOTZ (Global X Robotics & Artificial Intelligence ETF) is Robotics, automation, and AI companies globally. Managed by Global X, the fund carries $3.0B in assets under management, an expense ratio of 0.68%, a dividend yield of 0.54%. Its largest holding is Intuitive Surgical Inc (ISRG), which represents 9.9% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 5.7%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.